<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01504815</url>
  </required_header>
  <id_info>
    <org_study_id>M11ART</org_study_id>
    <nct_id>NCT01504815</nct_id>
  </id_info>
  <brief_title>Adaptive Radiation Treatment for Head and Neck Cancer</brief_title>
  <acronym>ARTFORCE</acronym>
  <official_title>Phase III Randomized Study With Cisplatinum and Conventional or Adaptive High Dose Radiotherapy for Advanced Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Catala de Salut</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Christie NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase III trial aims to:

      Explore the impact of pre-treatment information and radiation dose redistribution on
      locoregional control in patients with locally advanced SCCHN.

      The dose to the primary tumor with margins, based upon PET and CT information, will be
      inhomogeneously increased to a tumor dose between 70 and 84 Gy with decreasing dose towards
      the edges of the irradiated area.

      To determine the toxicity of combined modality treatment (cisplatin) with standard dose
      distribution versus combined modality treatment (cisplatin) with adaptive inhomogeneous
      radiation dose distribution.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>locoregional recurrence-free survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of patients with grade 3 toxicity or more</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life assessment</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>swallowing preservation</measure>
    <time_frame>1 year</time_frame>
    <description>Tube feeding dependency at one year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">268</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Cisplatinum + conventional RT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cisplatinum 100mg/m2 on days 1, 22 and 43, with conventional RT 70 Gy in 7 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisplatinum + adaptive high dose RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatinum, 100 mg/m2 on days 1, 22 and 43 with adaptive high dose RT to 84 Gy max on 50% uptake GTV in 7 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatinum</intervention_name>
    <description>i.v. 100 mg/m2 on days 1, 22 and 43 of radiotherapy</description>
    <arm_group_label>Cisplatinum + conventional RT</arm_group_label>
    <arm_group_label>Cisplatinum + adaptive high dose RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conventional radiotherapy</intervention_name>
    <description>conventional radiotherapy, 70Gy in 7 weeks</description>
    <arm_group_label>Cisplatinum + conventional RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Adaptive radiotherapy</intervention_name>
    <description>adaptive high dose radiotherapy up to 84 Gy max on 50% uptake GTV in 7 weeks</description>
    <arm_group_label>Cisplatinum + adaptive high dose RT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  biopsy-confirmed squamous cell carcinoma of the oropharynx, oral cavity or hypopharynx

          -  stage III/IV, T3-4, Nx M0

          -  &lt; 70 yrs

          -  glomerular filtration rate (GFR) &gt;60

          -  WHO 0-1

          -  no previous malignancies except for adequately treated basal cell carcinoma of the
             skin and carcinoma in situ of the cervix

          -  adequate bone marrow function, adequate hepatic function,informed consent

          -  &gt;18 years

        Exclusion Criteria:

          -  expected failure from follow-up

          -  previous malignancies except for adequately treated basal cell carcinoma of the skin
             and carcinoma in situ of the cervix

          -  expected inability to complete either one of the treatment arms

          -  pregnancy or lactation

          -  patients (m/f) with reproductive potential not implementing adequate contraceptive
             measures

          -  prior surgery, radiotherapy or chemotherapy for this tumor

          -  contraindications or serious concomitant diseases preventing the safe administration
             of chemotherapy and/or radiotherapy or are likely to interfere with the study
             assessments

          -  known active symptomatic fungal, bacterial and/or viral infections including HIV

          -  concomitant (or with 4 weeks before randomisation) administration of any other
             experimental drug

          -  concurrent treatment with any other anti-cancer therapy

          -  prior treatment with one or more of the active compounds
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olga Hamming-Vrieze, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olga Hamming-Vrieze, MD</last_name>
    <phone>+31205122135</phone>
    <email>o.vrieze@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Harry Bartelink, MD, PhD</last_name>
    <phone>+31205129111</phone>
    <email>h.bartelink@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy Cancer Institute</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yungan Tao, MD</last_name>
      <phone>+33 1 42116532</phone>
      <email>yungan.tao@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Yungan Tao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Hamming-Vrieze, MD</last_name>
      <phone>+31205122135</phone>
      <email>o.vrieze@nki.nl</email>
    </contact>
    <investigator>
      <last_name>Olga Hamming-Vrieze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roel Steenbakkers, MD, PhD</last_name>
      <email>r.steenbakkers@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Roel Steenbakkers, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastro Clinic</name>
      <address>
        <city>Maastricht</city>
        <zip>NL-6229 ET</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Hoebers, MD</last_name>
      <phone>+31 88 4455521</phone>
      <email>frank.hoebers@maastro.nl</email>
    </contact>
    <investigator>
      <last_name>Frank Hoebers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Centre</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Tans, MD, PhD</last_name>
      <email>l.tans@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Lisa Tans, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>NL-3508GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Terhaard, MD PhD</last_name>
      <phone>+31 88 7553137</phone>
      <email>c.h.j.terhaard@umcutrecht.nl</email>
    </contact>
    <investigator>
      <last_name>Chris Terhaard, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi Giralt, MD</last_name>
      <email>jgiralt@vhebron.net</email>
    </contact>
    <contact_backup>
      <last_name>Berta Garrido</last_name>
      <phone>+34 93 2746000</phone>
      <phone_ext>4695</phone_ext>
      <email>bgarrido@vhebron.net</email>
    </contact_backup>
    <investigator>
      <last_name>Jordi Giralt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska Institute</name>
      <address>
        <city>Stockholm</city>
        <zip>17177</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Herlestam, MD</last_name>
      <phone>+46 8 51770000</phone>
      <email>maria.herlestam-calero-moreno@karolinska.se</email>
    </contact>
    <investigator>
      <last_name>Teresa Herlestam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christie Hospital NHS Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 5BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Slevin, MD</last_name>
      <phone>+44 161 9187939</phone>
      <email>nick.slevin@christie.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Nick Slevin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2011</study_first_submitted>
  <study_first_submitted_qc>January 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2012</study_first_posted>
  <last_update_submitted>September 26, 2017</last_update_submitted>
  <last_update_submitted_qc>September 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced head and neck cancer</keyword>
  <keyword>adaptive radiotherapy</keyword>
  <keyword>cisplatinum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

